Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

This recent analysis found that, despite similar clinical outcomes, genomic differences were observed in mCRPC differences by race, highlighting the importance of racial diversity in future genomic ...

Dr. Matthew Smith answers the question: 'Hormone Refractory Prostate Cancer?' March 16, 2009 -- Question: What is hormone refractory prostate cancer? Answer: Nearly all men respond to initial ...

Treatment for Metastatic Hormone Sensitive Prostate Cancer, Talking with your Healthcare Team (Download - COMING SOON) ...

Former President Joe Biden is receiving radiation and hormone therapy as part of a new phase of treating the aggressive form ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early ...